Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering/ICN Rebetron agreement

Executive Summary

ICN will collect over $100 mil. in royalty payments from Schering-Plough for 1999 worldwide sales of oral ribavirin, ICN exec Benjamin Lapp told investors at Chase H&Q. The firm expects royalty contributions in 2000 to approach $200 mil. Lapp said, AAnalysts have guessed that the blended [royalty] rate is approximately 25%, and you wouldn=t make a huge miscalculation if you used that number.@ He added that ICN receives royalties from European sales in the 30% range. Schering has worldwide marketing rights to Rebetron, the combination of ICN=s ribavirin and Schering=s Intron A, for the hepatitis C indication. Schering recently added 120 Innovex sales reps to promote its hepatitis C products to primary care physicians. Currently 225 Schering reps promote the company=s hepatitis C products to gastroenterologists and hepatologists. Schering also markets Intron A as a single agent for treatment of hepatitis C

You may also be interested in...

ICN Spin-Off Ribapharm Expects Tiazole Phase III Results By 2002

Ribapharm expects to file an orphan drug application for the myelogenous leukemia treatment Tiazole (tiazofurin) following completion of a Phase III trial by the end of 2002.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts